BR112014025299A2 - ANTICORPO DE REAÇÃO CRUZADA DIRIGIDO CONTRA STAPHYLOCOCCUS AUREUS, PREPARAÇÃO FARMACEUTICA E DIAGNÓSTICA COMPREENDENDO O ANTiCORPO, MÉTODOS DE ANTICORPO DE REAÇÃO CRUZADA CONTRA STAPHYLOCOCCUS AUREUS - Google Patents

ANTICORPO DE REAÇÃO CRUZADA DIRIGIDO CONTRA STAPHYLOCOCCUS AUREUS, PREPARAÇÃO FARMACEUTICA E DIAGNÓSTICA COMPREENDENDO O ANTiCORPO, MÉTODOS DE ANTICORPO DE REAÇÃO CRUZADA CONTRA STAPHYLOCOCCUS AUREUS

Info

Publication number
BR112014025299A2
BR112014025299A2 BR112014025299A BR112014025299A BR112014025299A2 BR 112014025299 A2 BR112014025299 A2 BR 112014025299A2 BR 112014025299 A BR112014025299 A BR 112014025299A BR 112014025299 A BR112014025299 A BR 112014025299A BR 112014025299 A2 BR112014025299 A2 BR 112014025299A2
Authority
BR
Brazil
Prior art keywords
antibody
cross reaction
pharmaceutical
staphylococcus aureus
methods
Prior art date
Application number
BR112014025299A
Other languages
English (en)
Other versions
BR112014025299A8 (pt
Inventor
Eszter Nagy
Adriana Badarau
Harald Rouha
Lukas Stulik
Gabor Nagy
Irina Mirkina
Zoltan Magyarics
Zehra Visram
Michaela Jaegerhofer
Manuel Zerbs
Ivana Dolezilkova
Astrid Teubenbacher
Michael Benjamin Battles
Bianka Dominique Prinz
Original Assignee
Arsanis Biosciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arsanis Biosciences Gmbh filed Critical Arsanis Biosciences Gmbh
Publication of BR112014025299A2 publication Critical patent/BR112014025299A2/pt
Publication of BR112014025299A8 publication Critical patent/BR112014025299A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112014025299A 2012-04-17 2013-04-17 anticorpo de reação cruzada dirigido contra staphylococcus aureus, preparação farmacêutica e diagnóstica compreendendo o anticorpo, métodos de anticorpo de reação cruzada contra staphylococcus aureus BR112014025299A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12164506 2012-04-17
EP13151010 2013-01-11
PCT/EP2013/058022 WO2013156534A1 (en) 2012-04-17 2013-04-17 Cross-reactive staphylococcus aureus antibody

Publications (2)

Publication Number Publication Date
BR112014025299A2 true BR112014025299A2 (pt) 2013-10-24
BR112014025299A8 BR112014025299A8 (pt) 2018-01-16

Family

ID=48607210

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014025299A BR112014025299A8 (pt) 2012-04-17 2013-04-17 anticorpo de reação cruzada dirigido contra staphylococcus aureus, preparação farmacêutica e diagnóstica compreendendo o anticorpo, métodos de anticorpo de reação cruzada contra staphylococcus aureus

Country Status (18)

Country Link
US (1) US9914767B2 (pt)
EP (1) EP2668208B1 (pt)
JP (1) JP6228186B2 (pt)
CN (1) CN104640878B (pt)
AU (1) AU2013251165B2 (pt)
BR (1) BR112014025299A8 (pt)
CA (1) CA2870223A1 (pt)
DK (1) DK2668208T3 (pt)
ES (1) ES2546105T3 (pt)
HU (1) HUE025378T2 (pt)
IL (1) IL235089B (pt)
MX (1) MX355985B (pt)
NZ (1) NZ700578A (pt)
PL (1) PL2668208T3 (pt)
PT (1) PT2668208E (pt)
RU (1) RU2014145830A (pt)
WO (1) WO2013156534A1 (pt)
ZA (1) ZA201407330B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014187746A2 (en) * 2013-05-21 2014-11-27 Arsanis Biosciences Gmbh Generation of highly potent antibodies neutralizing the lukgh (lukab) toxin of staphylococcus aureus
EP3011012B1 (en) * 2013-06-18 2018-09-12 New York University Cellular factors involved in the cytotoxicity of staphylococcus aureus leukocidins: novel therapeutic targets
JP6473746B2 (ja) * 2013-10-17 2019-02-20 アルサニス・バイオサイエンスズ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 交差反応性黄色ブドウ球菌抗体配列
CA2932819A1 (en) 2013-12-09 2015-06-18 New York University Compositions and methods for phagocyte delivery of anti-staphylococcal agents
JP2017524943A (ja) * 2014-08-12 2017-08-31 アルサニス・バイオサイエンスズ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｓ．アウレウス疾患の予測
RU2017139800A (ru) * 2015-04-17 2019-05-17 Арсанис Байосайенсиз Гмбх Комбинированный препарат антител против staphylococcus aureus
TWI781130B (zh) 2017-01-03 2022-10-21 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
AU2018285857B2 (en) * 2017-06-13 2022-10-06 Abvacc, Inc. Immunogenic compositions comprising Staphylococcus aureus leukocidin lukA and lukB derived polypeptides
CN109384844B (zh) * 2017-08-04 2020-12-18 中国人民解放军军事医学科学院基础医学研究所 一种抗金黄色葡萄球菌α溶血素单克隆抗体及应用
KR102061735B1 (ko) * 2018-06-08 2020-01-02 대한민국(농림축산식품부 농림축산검역본부장) 황색포도알균 약독화 장독소 및 세포독소 재조합 단백질을 포함하는 백신 조성물
WO2023213393A1 (en) * 2022-05-04 2023-11-09 Evaxion Biotech A/S Staphylococcal protein variants and truncates
CN116789813B (zh) * 2023-06-27 2024-04-26 重庆原伦生物科技有限公司 一种抗金黄色葡萄球菌α-溶血素的单克隆抗体及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
KR20150140417A (ko) 2004-07-22 2015-12-15 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
EP2043690A1 (en) 2006-06-12 2009-04-08 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
JP2008013447A (ja) 2006-07-03 2008-01-24 Juntendo 毒素検出方法
CA2697193C (en) 2007-09-14 2017-06-06 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP2284193A1 (en) 2009-08-10 2011-02-16 Kenta Biotech AG Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation
LT3444268T (lt) 2010-05-05 2022-04-11 New York University Staphylococcus aureus leukocidinai, terapinės kompozicijos ir jų panaudojimo būdai
AU2011279073B2 (en) 2010-07-16 2016-06-09 Adimab, Llc Antibody libraries

Also Published As

Publication number Publication date
RU2014145830A (ru) 2016-06-10
PT2668208E (pt) 2015-10-12
CN104640878A (zh) 2015-05-20
JP2015515479A (ja) 2015-05-28
MX2014012501A (es) 2015-03-19
US9914767B2 (en) 2018-03-13
JP6228186B2 (ja) 2017-11-08
EP2668208A1 (en) 2013-12-04
ZA201407330B (en) 2016-05-25
EP2668208B1 (en) 2015-06-03
CA2870223A1 (en) 2013-10-24
AU2013251165B2 (en) 2017-08-24
IL235089B (en) 2019-03-31
ES2546105T3 (es) 2015-09-18
US20150086539A1 (en) 2015-03-26
DK2668208T3 (en) 2015-08-31
MX355985B (es) 2018-05-07
BR112014025299A8 (pt) 2018-01-16
NZ700578A (en) 2017-03-31
HUE025378T2 (hu) 2016-02-29
WO2013156534A1 (en) 2013-10-24
AU2013251165A1 (en) 2014-10-16
CN104640878B (zh) 2018-12-04
WO2013156534A9 (en) 2014-03-13
PL2668208T3 (pl) 2015-12-31

Similar Documents

Publication Publication Date Title
BR112014025299A2 (pt) ANTICORPO DE REAÇÃO CRUZADA DIRIGIDO CONTRA STAPHYLOCOCCUS AUREUS, PREPARAÇÃO FARMACEUTICA E DIAGNÓSTICA COMPREENDENDO O ANTiCORPO, MÉTODOS DE ANTICORPO DE REAÇÃO CRUZADA CONTRA STAPHYLOCOCCUS AUREUS
CL2015001486A1 (es) Composición que comprende agentes de control biológico.
BR112015002738A2 (pt) composto , e , composição farmacêutica
BR112015003259A2 (pt) composto, composição farmacêutica, e, composição de vacina.
BR112014025695A2 (pt) Preparação de amostra de ácido nucleico
BR112014031335A2 (pt) bloco de diagnóstico transacional
FR2997014B1 (fr) Composition sterile dermo-injectable
BR112013019281A2 (pt) composição inovadora de pesticidas.
BR112014009889A2 (pt) compostos dissubstituídos, compostos e composição farmacêutica
BR112015004938A2 (pt) combinações de compostos ativos
BR112015009546A2 (pt) compostos e seus processos de preparação, composições farmacêuticas e misturas ou associações farmacêuticas
BR112014028871A2 (pt) linhagens de propionibacterium.
SG11201503231YA (en) METHODS OF TREATING <i>S. AUREUS</i>-ASSOCIATED DISEASES
BR112015023620A2 (pt) preparação de malto-oligossacarídeos.
CL2014003283A1 (es) Formulación farmacéutica.
BR112015010797A2 (pt) compostos aniônicos substituídos, e, composição farmacêutica
BR112014026557A2 (pt) fralda descartável.
UA25626S (uk) Печиво
BR112015010271A2 (pt) produto de comicronização, composição farmacêutica e seus usos
BR112014030277A2 (pt) sistema médico
BR112013019284A2 (pt) composição inovadora de pesticidas.
BR112015002923A2 (pt) compostos antibacterianos.
CO7091176A2 (es) Diagnóstico farmacéutico
DK3473255T3 (da) Farmaceutisk formulering omfattende ciclesonid
BR112014028443A2 (pt) composição estéril.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 11.2 NA RPI NO 2551 DE 26/11/2019 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2562 DE 11/02/2020.